Cyclooxygenase-2 expression is higher in ovarian cancer tissue adjacent to endometriosis than in ovarian cancer without comorbid endometriosis.
OBJECTIVE
The purpose of this study was to examine if COX-2, CK7 and CK20 are involved in the malignant transformation of endometriosis.


METHODS
We compared COX-2, CK7 and CK20 expressions between isolated endometriosis lesions and endometriosis lesions adjacent to ovarian carcinoma and between isolated ovarian carcinoma and ovarian carcinoma with implants of endometriosis. Immunoreactivity was quantified using an immunohistochemical scoring system that corresponds to an image analysis-based system.


RESULTS
There was no difference in COX-2, CK7 and CK20 expressions between the isolated endometriosis lesions and the endometriosis lesions adjacent to ovarian carcinoma. Similarly, CK7 and CK20 were equally expressed between the isolated ovarian carcinoma and the ovarian carcinoma with implants of endometriosis. The COX-2 over-expression rate was greater in ovarian carcinoma that was associated with endometriosis than in isolated ovarian carcinoma (27.8% versus 5.6%, P = 0.083). In endometrioid type ovarian carcinoma, the difference in COX-2 expression was statistically significant (50% versus 0%, P = 0.023).


CONCLUSIONS
COX-2 over-expression may be a result of the malignant transformation of endometriosis to endometrioid type ovarian cancer or may represent an interaction between the two cellular components. With respect to cytokeratins, neither CK7 nor CK20 appear to be involved in the malignant transformation of endometriosis.
Chou
Yu-Ching
YC
Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, 201 Section 2, Shih-Pai Road, Taipei 11217, Taiwan.
Chen
Yi-Jen
YJ
Lai
Chiung-Ru
CR
Wang
Peng-Hui
PH
Hsin-Chan
Yuan
Chiou-Chung
CC
D018269:Carcinoma, Endometrioid / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000096:biosynthesis*; D004715:Endometriosis / Q000150:complications*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053554:Keratin-20; D053552:Keratin-7; D007633:Keratins / Q000096:biosynthesis; D010051:Ovarian Neoplasms / Q000150:complications* / Q000201:enzymology*
C507499:KRT20 protein, human; C507497:KRT7 protein, human; D053554:Keratin-20; D053552:Keratin-7; D007633:Keratins; D051546:Cyclooxygenase 2